



Chengdu Huasun Group Inc., Ltd. 成都华舜集团

<http://www.huasungrp.com>

Bilateral Meetings

- Tuesday (09:00 am - 01:30 pm)
- Tuesday (14:00 pm - 17:00 pm)

Description

Chengdu Huasun Group Inc., Ltd. [Stock code: 000790] is an industrial group, which base on modern Tcm and featured by its bio-pharmaceuticals, was listed in Shenzhen Stock Exchange in 1998. It has the world's first monoclonal antibody RIA targeted drugs used in the treatment of primary hepatocellular carcinoma-Licartin [Iodine-131] Metuximab monoclonal antibody Injection, Sanchi Tongshu Capsule, Biyuanshu oral liquid/capsule, Huolishu oral liquid and other products. [Stock code: 000790] 1998年12月18日在深圳证券交易所上市。公司主要从事现代中药、生物制药、化学制药、医疗器械的研发、生产和销售。主要产品有：利卡汀注射液、[131I]美妥昔单抗注射液、三奇通舒胶囊、比玉元舒口服液/胶囊、华立舒口服液和其他产品。

Organization Type

Big Company / corporation,

Country

China

City

Chengdu, Hi-Tech Zone [Google map](#)

Areas of Activities

Health biotechnologies

Business Request

Cooperate with European companies in pharmaceutical field, and Seek EU partners for clinical trial a

In order to achieve the globalization of Chinese medicinal product, our company plans to communicate and cooperate with European companies in pharmaceutical field, to jointly develop and register our product. In the next few years, the company also expects to find other cooperation partners in Europe, such as Contract research organization for clinical trial and distributors for prescription drugs etc.

为了实现中国中药产品的全球化，我们公司计划与欧洲医药企业沟通合作，共同开发和注册我们的产品。在接下来的几年里，公司也期望在欧洲找到其他合作伙伴，如合同研究组织用于临床试验和处方药的经销商等。

Cooperation Offered

1. Outsourcing co-operation
2. Technical co-operation
3. License agreement
4. Manufacturing agreement
5. Sales / Distribution

Cooperation Requested

- 1. Outsourcing co-operation**
- 2. Technical co-operation**
- 3. License agreement**
- 4. Manufacturing agreement**
- 5. Sales / Distribution**